Loading stock data…
IOVA
$3.40+0.04 (+1.19%)
Market ClosedLast close May 1
Iovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Iovance Biotherapeutics, Inc. in the Healthcare sector is trading at $3.40. The stock is currently 40% below its 52-week high of $5.63, remaining 23.2% above its 200-day moving average. Technical signals show neutral RSI of 47 and bearish MACD signal, explaining why IOVA maintains its current momentum and trend strength. The Whystock Score of 55/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 47) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$3.40
Potential Upside
5%
Whystock Fair Value$3.57
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus10 analysts
Buy
Mean target$9.00+164.7%
Range$4.00 – $16.00
Fundamentals
Iovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the Unite...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.45B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.76
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-55.82%
Volume
Today's trading volume
9.83M
Recent News
Pacira (PCRX) Q1 Earnings Miss Estimates
Pacira (PCRX) delivered earnings and revenue surprises of -1.64% and +0.58%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Iovance Biotherapeutics (IOVA) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Iovance Biotherapeutics (IOVA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Iovance Share Increase Proposal Weighs Dilution Risk Against TIL Growth Funding
Iovance Biotherapeutics, listed as NasdaqGM:IOVA, has proposed a significant increase to its authorized common stock. Shareholders are scheduled to vote on the proposal at the company’s upcoming annual meeting. The authorization change would give the company more flexibility for future equity issuances, subject to board approval. Iovance Biotherapeutics focuses on cell therapies targeting cancer, an area that often requires substantial capital for clinical development, manufacturing...
Regeneron (REGN) Surpasses Q1 Earnings and Revenue Estimates
Regeneron (REGN) delivered earnings and revenue surprises of +11.18% and +4.88%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Is Viking Therapeutics, Inc. (VKTX) A Good Stock To Buy Now?
Is VKTX a good stock to buy? We came across a bullish thesis on Viking Therapeutics, Inc. on Charlie Evans’s Substack by Charlie Evans PhD. In this article, we will summarize the bulls’ thesis on VKTX. Viking Therapeutics, Inc.’s share was trading at $35.53 as of April 20th. Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies […]